Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data

Background: Globally, prostate cancer is the second most common malignancy in males and fifth leading cancer-related cause of death. To build a reliable predictive system for screening performance, the study looking into the risk factors of BM in prostate cancer patients is warranted. Aim: Using the Surveillance, Epidemiology, and End Results database (SEER) to assess the incidence, and risk factors of morbidity and prognosis for bone metastases in initial metastatic prostate cancer. Methods: A total of 249,331 prostate cancer patients who were diagnosed between 2010 and 2014 in SEER database were obtained to investigate the risk factors for developing bone metastasis, and 9925 of them who registered before 2013 were retrieved (with at least 1 year follow-up) to explore the prognostic factors for bone metastasis. Multivariate logistic and Cox regression were used to identify risk factors and prognostic factors for bone metastases, respectively. Results: Totally, 12,794 patients (5.1%) were diagnosed with bone metastases at the initial diagnosis. Older age, unmarried status, higher tumor stage, lymph node metastasis, metastases at lung brain and liver were the homogeneous risk factors for the morbidity and prognosis of bone metastasis in prostate cancer. Race and histologic differentiation grade were the heterogeneities associated factors. Black race was positively associated with bone metastasis morbidity; however, it has no significant effect on the prognosis. Poor differentiated grade may be the risk factors for developing bone metastasis; however, grade II was negatively associated with prognosis of bone metastasis. Conclusion: The survival of prostate cancer was poor with the bone metastasis approximate 5%. The prostate cancer has homogeneous and heterogeneities risk factors for incidence and prognosis of bone metastasis, which may provide potential guideline for the screening and preventive treatment of the bone metastasis of prostate cancer.

Download Full-text

214: Incidence and Risk Factors of Symptomatic DVT in Prostate Cancer Patients Undergoing Laparoscopic Radical Prostatectomy

The Journal of Urology ◽

10.1016/s0022-5347(18)32481-9 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 70-71

Author(s):

Fernando P. Secin ◽

Clément-Claude Abbou ◽

Inderbir S. Gill ◽

Georges Fournier ◽

Thierry Piéchaud ◽

...

Keyword(s):

Prostate Cancer ◽

Risk Factors ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Laparoscopic Radical Prostatectomy

Download Full-text

The homogeneous and heterogeneous risk factors for occurrence and prognosis in lung cancer patients with bone metastasis

Journal of Bone Oncology ◽

10.1016/j.jbo.2019.100251 ◽

2019 ◽

Vol 17 ◽

pp. 100251 ◽

Cited By ~ 3

Author(s):

Ben Wang ◽

Lijie Chen ◽

Chongan Huang ◽

Jialiang Lin ◽

Xiangxiang Pan ◽

...

Keyword(s):

Risk Factors ◽

Lung Cancer ◽

Bone Metastasis ◽

Cancer Patients ◽

Lung Cancer Patients

Download Full-text

MO27-2 Risk factors for metastasis in prostate cancer patients: A systematic review

Annals of Oncology ◽

10.1016/j.annonc.2021.05.630 ◽

2021 ◽

Vol 32 ◽

pp. S315

Author(s):

Billy Susanto ◽

Griffin Geraldo ◽

Jennifer Jesse Limanto ◽

Andree Kurniawan

Keyword(s):

Prostate Cancer ◽

Risk Factors ◽

Systematic Review ◽

Cancer Patients

Download Full-text

Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients

Journal of Immunotherapy ◽

10.1097/cji.0b013e3181f5dac7 ◽

2010 ◽

Vol 33 (9) ◽

pp. 999-1005 ◽

Cited By ~ 27

Author(s):

Richard Harrop ◽

William Shingler ◽

Michelle Kelleher ◽

Jackie de Belin ◽

Peter Treasure

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Cancer Patients ◽

Clinical Data ◽

Trial Analysis ◽

Phase I And Ii

Download Full-text

Lesion-Based Bone Metastasis Detection in Chest Bone Scintigraphy Images of Prostate Cancer Patients Using Pre-Train, Negative Mining, and Deep Learning

Diagnostics ◽

10.3390/diagnostics11030518 ◽

2021 ◽

Vol 11 (3) ◽

pp. 518

Author(s):

Da-Chuan Cheng ◽

Te-Chun Hsieh ◽

Kuo-Yang Yen ◽

Chia-Hung Kao

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Deep Learning ◽

Bone Metastasis ◽

Cancer Patients ◽

Bone Scintigraphy ◽

Breast Cancer Patients ◽

Location Detection ◽

The Mean ◽

Mean Sensitivity

This study aimed to explore efficient ways to diagnose bone metastasis early using bone scintigraphy images through negative mining, pre-training, the convolutional neural network, and deep learning. We studied 205 prostate cancer patients and 371 breast cancer patients and used bone scintigraphy data from breast cancer patients to pre-train a YOLO v4 with a false-positive reduction strategy. With the pre-trained model, transferred learning was applied to prostate cancer patients to build a model to detect and identify metastasis locations using bone scintigraphy. Ten-fold cross validation was conducted. The mean sensitivity and precision rates for bone metastasis location detection and classification (lesion-based) in the chests of prostate patients were 0.72 ± 0.04 and 0.90 ± 0.04, respectively. The mean sensitivity and specificity rates for bone metastasis classification (patient-based) in the chests of prostate patients were 0.94 ± 0.09 and 0.92 ± 0.09, respectively. The developed system has the potential to provide pre-diagnostic reports to aid in physicians’ final decisions.

Download Full-text

Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in prostate cancer patients: Influence of Gleason score, treatment and bone metastasis

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2012.12.004 ◽

2013 ◽

Vol 67 (3) ◽

pp. 203-208 ◽

Cited By ~ 10

Author(s):

Vanessa Battisti ◽

Liési D.K. Maders ◽

Margarete D. Bagatini ◽

Iara E. Battisti ◽

Luziane P. Bellé ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Adenosine Deaminase ◽

Cancer Patients ◽

Gleason Score

Download Full-text

Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.02.9439 ◽

2006 ◽

Vol 24 (13) ◽

pp. 1982-1989 ◽

Cited By ~ 58

Author(s):

Norihiko Tsuchiya ◽

Lizhong Wang ◽

Hiroyoshi Suzuki ◽

Takehiko Segawa ◽

Hisami Fukuda ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Cancer Patients ◽

Genetic Polymorphisms ◽

Metastatic Prostate Cancer ◽

Genetic Factors ◽

Response To Treatment ◽

Logrank Test ◽

Ca Repeat ◽

Igf I

Purpose The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. Patients and Methods One hundred eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software. Results Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001). Conclusion The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.

Download Full-text